Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to MacroGenics
Related studies linked through entity extraction aliases.
Safety Study of MGA271 in Refractory Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes
- Status
- TERMINATED
- Phase
- PHASE1
Safety Study of MGAH22 in HER2-positive Carcinomas
- Status
- COMPLETED
- Phase
- PHASE1
Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Treatment of West Nile Virus With MGAWN1
- Status
- TERMINATED
- Phase
- PHASE2
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
- Status
- TERMINATED
- Phase
- PHASE3
Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)
- Status
- TERMINATED
- Phase
- NA
Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE2
A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults
- Status
- COMPLETED
- Phase
- PHASE1
The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1